EA201992121A1 - HETEROCYCLIC COMPOUNDS APPLICABLE IN THE TREATMENT OF DISEASES - Google Patents

HETEROCYCLIC COMPOUNDS APPLICABLE IN THE TREATMENT OF DISEASES

Info

Publication number
EA201992121A1
EA201992121A1 EA201992121A EA201992121A EA201992121A1 EA 201992121 A1 EA201992121 A1 EA 201992121A1 EA 201992121 A EA201992121 A EA 201992121A EA 201992121 A EA201992121 A EA 201992121A EA 201992121 A1 EA201992121 A1 EA 201992121A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
treatment
heterocyclic compounds
fibrosis
compounds applicable
Prior art date
Application number
EA201992121A
Other languages
Russian (ru)
Other versions
EA038294B1 (en
Inventor
Грэхем Битон
Фабио К. Туччи
Сатиш Б. Равула
Чандравадан Р. Шах
Хиеп Луу
Original Assignee
Эпиджен Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпиджен Байосайенсиз, Инк. filed Critical Эпиджен Байосайенсиз, Инк.
Publication of EA201992121A1 publication Critical patent/EA201992121A1/en
Publication of EA038294B1 publication Critical patent/EA038294B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны гетероциклические соединения, представляющие собой лиганды рецепторов лизофосфатидной кислоты, применимые в лечении заболеваний и состояний, зависимых от рецепторов лизофосфатидной кислоты, в том числе, без ограничения, заболеваний, включающих фиброз, такой как фиброз сердца, почки, печени и легкого, и склеродермию; воспалительных заболеваний, таких как диабетическая нефропатия и воспалительное заболевание кишечника; заболеваний глаз, таких как заболевания, включающие дегенерацию сетчатки; нервных заболеваний, таких как зуд и боль. Неограничивающие примеры этих соединений включают (RS)-3-циклопропил-2-{4-[3-метил-4-((R)-1-фенилэтоксикарбониламино)изоксазол-5-ил]бензилокси}пропионовую кислоту и (R)-1-(4'-{5-[1-(2-хлорфенил)этоксикарбониламино]-4-фторпиразол-1-ил}-2-фтордифенил-4-ил)циклопропанкарбоновую кислоту.Described are heterocyclic compounds that are ligands of lysophosphatidic acid receptors useful in the treatment of diseases and conditions dependent on lysophosphatidic acid receptors, including, but not limited to, diseases including fibrosis such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; eye diseases such as diseases including retinal degeneration; nervous diseases such as itching and pain. Non-limiting examples of these compounds include (RS) -3-cyclopropyl-2- {4- [3-methyl-4 - ((R) -1-phenylethoxycarbonylamino) isoxazol-5-yl] benzyloxy} propionic acid and (R) -1 - (4 '- {5- [1- (2-chlorophenyl) ethoxycarbonylamino] -4-fluoropyrazol-1-yl} -2-fluorodiphenyl-4-yl) cyclopropanecarboxylic acid.

EA201992121A 2013-05-24 2014-03-17 Heterocyclic compounds useful in the treatment of diseases EA038294B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361827409P 2013-05-24 2013-05-24

Publications (2)

Publication Number Publication Date
EA201992121A1 true EA201992121A1 (en) 2020-02-03
EA038294B1 EA038294B1 (en) 2021-08-05

Family

ID=69636705

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992121A EA038294B1 (en) 2013-05-24 2014-03-17 Heterocyclic compounds useful in the treatment of diseases

Country Status (1)

Country Link
EA (1) EA038294B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060819A1 (en) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
MX2013006040A (en) * 2010-12-07 2013-08-26 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
SG2014011555A (en) * 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
EA038294B1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
EA201591607A8 (en) HETEROCYCLIC COMPOUNDS APPLICABLE IN THE TREATMENT OF DISEASES
EA201591908A1 (en) Condensed Heterocyclic Compounds As Protein Kinase Inhibitors
EA201791002A1 (en) NEW CONNECTIONS MODULATING FXR (NR1H4)
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
RU2017127135A (en) THERAPEUTICALLY AGAINST CANCER OF CANCER
PE20160521A1 (en) AUTOTAXIN INHIBITORS INCLUDING A HETEROAROMATIC-BENZYL-AMIDE RING CYCLICAL NUCLEUS
PH12015502794A1 (en) Pyrimidinedione compounds against cardiac conditions
EA201500574A1 (en) NEW INDANILOXYDYHYDROBENZOFURANILETACIC ACIDS
AU2016219612A1 (en) Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
NZ604831A (en) Apoptosis signal-regulating kinase inhibitors
MX2015016029A (en) Heterocyclic compounds as pest control agents.
EA202091120A3 (en) 2,4-THIAZOLINIDONE DERIVATIVES IN TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
EA201790599A1 (en) COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS
CL2011001848A1 (en) Compounds derived from pyrimidine fused to a 5-membered heterocycle; angiotensin ii receptor antagonist, peroxisome proliferator receptor agonist; pharmaceutical composition; and use of the compounds in the treatment of circulatory diseases such as hypertension, heart disease, arteriosclerosis, among others.
EA201790206A1 (en) NEW 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS
MX366293B (en) Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders.
EA201390070A1 (en) TREATMENT OF DISORDERS CAUSED BY L-DOPA, DOPAMIN AGONIST AND / OR AMPLIFIER DOPAMINE
EA201691244A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A COMPOUND OF THE PYRIDYLAMINOACIC ACID
EA201791021A1 (en) 1- [2- (AMINOMETHYL) BENZYL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO [3,2-d] PYRIMIDIN-4-ONE AS INHIBITORS MYELOPEROXIDASE
MX370430B (en) Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses.
EA201790080A1 (en) CRYSTALLINE O-METHYLOXIM (3Z, 5S) -5- (HYDROXYMETHYL) -1 - [(2'-METHYL-1,1'-BIPHENYL-4-IL) CARBONYL] PYRROLIDIN-3-OH, USEFUL IN THE METHODS OF TREATING THE TREAD RELATED TO OT-R ACTIVITY
EA201890524A1 (en) (S, E) -3- (6-AMINOPYRIDIN-3-IL) -N - ((5- (4- (3-Fluoro-3-Methylpyrrolidin-1-Carbonyl) phenyl) -7- (4-Fluoro-phenyl) BENZOFURAN-2-IL) METHYL ACRYLAMIDE FOR THE TREATMENT OF CANCER
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201790209A1 (en) NEW 2.5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS
EA201992121A1 (en) HETEROCYCLIC COMPOUNDS APPLICABLE IN THE TREATMENT OF DISEASES